早期强化胰岛素治疗可改善新确诊2型糖尿病病人胰岛Beta细胞功能

NEW YORK (Reuters Health) May 22 - Early intensive insulin therapy in newly diagnosed type 2 diabetics can enhance beta-cell function and lead to extended glycemic remissions, according to a report in the May 24th issue of The Lancet.
纽约路透社健康专栏5月22日报道：根据5月24日发表在《柳叶刀》上的一篇研究报告，早期强化胰岛素治疗可改善新确诊2型糖尿病病人胰岛Beta细胞功能，并能缓解高血糖状态。

Prior research has suggested that such therapy could positively influence the natural course of type 2 diabetes, Dr. Jianping Weng, from the Third Affiliated Hospital of Sun Yat-Sen University in Guangzhou, China, and colleagues note.
广州市中山大学第三附属医院的翁建平医生和他的同事注意到，先前的研究提示早期强化胰岛素治疗可对2型糖尿病的自然病程产生积极的影响。

To investigate, the research team assessed the outcomes of 382 patients who were randomized to receive treatment with insulin given either in a continuous subcutaneous infusion or as multiple daily injections, or standard oral agents.
为了进一步研究，研究小组评估了382名患者的预后情况。该试验中的382名患者随机分为2组，分别接受连续胰岛素皮下输注或每日多重注射治疗，或者标准化口服降糖药治疗。（multiple daily injections不知翻译的准不准确，向高人请教）

Treatment with the assigned agent was stopped after normoglycemia was achieved for 2 weeks. The subjects then switched to diet and exercise management alone.
待血糖达正常2周后，停止药物治疗，改为单纯控制饮食和运动疗法。

With early intensive insulin therapy, nearly all patients achieved target glycemic control within 4 to 6 days, the report indicates. With oral drug therapy, by contrast, subjects often needed 9 days or longer to achieve control.
研究表明，糖尿病早期接受强化胰岛素治疗患者的血糖几乎在4-6天内达标，相比较之下，接受口服降糖药物治疗患者的血糖需要9天或更长的时间才达标。

The 1-year glycemic remission rates with the insulin infusion and injection protocols were 51.1% and 44.9%, respectively. With oral drug therapy, the glycemic remission rate was just 26.7%.
胰岛素输注治疗和注射治疗的高血糖1年缓解率分别是51.1%和 44.9%，而口服药物治疗的高血糖缓解率仅为26.7%。

HOMA B, which is a measure of basal beta-cell function, and insulin response results indicated that the intensive insulin regimens significantly improved the recovery and maintenance of beta-cell function.
测量胰岛Beta细胞功能的测量方法HOMA B和胰岛素反应的结果显示早期强化胰岛素治疗可显著改善并维持Beta细胞的功能。

In a related editorial, Drs. Ravi Retnakaran and Daniel J. Drucker, from the University of Toronto, comment, "Although the relevant biological mechanisms and target tissues contributing to preferential improvement in beta-cell function remain unclear, these data suggest that the use of intensive insulin therapy early in the course of type 2 diabetes warrants further clinica investigation."
来自多伦多大学的Ravi Retnakaran医生和Daniel J. Drucker医生在最近的社论中评论道“虽然改善Beta细胞功能的相关生理机制和靶组织仍不清楚，但是这些数据显示早期强化胰岛素治疗2型糖尿病值得进一步做临床研究。


译者：qifangfang6666
转自 dxy.cn